mercredi 5 septembre 2012

FDA approves new treatment for a type of late stage prostate cancer

The U.S. Food and Drug Administration recently approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.

Aucun commentaire:

Enregistrer un commentaire